Novo Nordisk to start phase III trial with tablet for Alzheimer's
Novo Nordisk plans to start a phase III trial with semaglutide against Alzheimer's disease during the first half of 2021, states the firm in a company announcement.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
After many external research results with GLP-1 drugs used to treat Alzheimer's disease have been publicly presented, Novo Nordisk has opted to initiate its own research program, which the pharmaceutical company states on Wednesday afternoon in a company announcement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo after crucial data from competitor: Welcomes drug R&D
For subscribers
